| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinocerebellar Ataxias | 101 | 2025 | 252 | 18.660 |
Why?
|
| Myotonic Dystrophy | 46 | 2023 | 148 | 5.060 |
Why?
|
| Machado-Joseph Disease | 21 | 2023 | 25 | 4.600 |
Why?
|
| Ataxin-10 | 25 | 2025 | 28 | 4.220 |
Why?
|
| Microsatellite Repeats | 21 | 2022 | 219 | 4.160 |
Why?
|
| Trinucleotide Repeat Expansion | 38 | 2025 | 124 | 4.030 |
Why?
|
| DNA Repeat Expansion | 35 | 2025 | 64 | 3.410 |
Why?
|
| Cerebellar Ataxia | 11 | 2023 | 66 | 3.170 |
Why?
|
| Nerve Tissue Proteins | 34 | 2024 | 1113 | 2.720 |
Why?
|
| Ataxia | 12 | 2023 | 168 | 2.140 |
Why?
|
| RNA | 10 | 2023 | 568 | 1.780 |
Why?
|
| Spinocerebellar Degenerations | 9 | 2024 | 64 | 1.570 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 19 | 2010 | 369 | 1.550 |
Why?
|
| Friedreich Ataxia | 18 | 2024 | 48 | 1.540 |
Why?
|
| Epilepsy | 13 | 2025 | 873 | 1.440 |
Why?
|
| Trinucleotide Repeats | 23 | 2017 | 110 | 1.320 |
Why?
|
| Induced Pluripotent Stem Cells | 6 | 2020 | 195 | 1.310 |
Why?
|
| Humans | 266 | 2025 | 124797 | 1.250 |
Why?
|
| Mutation | 40 | 2020 | 5812 | 1.230 |
Why?
|
| Cerebellum | 11 | 2023 | 416 | 1.200 |
Why?
|
| Huntington Disease | 16 | 2014 | 143 | 1.180 |
Why?
|
| Haplotypes | 13 | 2024 | 520 | 1.180 |
Why?
|
| Neural Stem Cells | 5 | 2018 | 124 | 1.100 |
Why?
|
| Phenotype | 36 | 2021 | 4261 | 1.070 |
Why?
|
| Adult | 116 | 2025 | 29472 | 1.030 |
Why?
|
| Genetic Testing | 13 | 2019 | 1004 | 0.990 |
Why?
|
| Gene Frequency | 8 | 2024 | 719 | 0.960 |
Why?
|
| Middle Aged | 103 | 2025 | 26717 | 0.940 |
Why?
|
| Purkinje Cells | 2 | 2019 | 159 | 0.940 |
Why?
|
| Ataxin-3 | 9 | 2021 | 10 | 0.920 |
Why?
|
| Male | 146 | 2025 | 61285 | 0.880 |
Why?
|
| Disease Progression | 16 | 2025 | 2055 | 0.870 |
Why?
|
| Nerve Degeneration | 3 | 2014 | 126 | 0.870 |
Why?
|
| Alleles | 30 | 2024 | 1618 | 0.860 |
Why?
|
| Genotype | 21 | 2020 | 2557 | 0.860 |
Why?
|
| Neuromuscular Diseases | 4 | 2017 | 56 | 0.840 |
Why?
|
| Age of Onset | 34 | 2025 | 582 | 0.840 |
Why?
|
| Pedigree | 36 | 2021 | 1596 | 0.830 |
Why?
|
| Polymorphism, Genetic | 13 | 2013 | 812 | 0.810 |
Why?
|
| DNA | 19 | 2011 | 1600 | 0.790 |
Why?
|
| Peptides | 7 | 2021 | 794 | 0.770 |
Why?
|
| DNA, Catalytic | 1 | 2021 | 3 | 0.760 |
Why?
|
| Brazil | 15 | 2025 | 123 | 0.740 |
Why?
|
| Repressor Proteins | 9 | 2020 | 820 | 0.720 |
Why?
|
| Female | 128 | 2025 | 66555 | 0.720 |
Why?
|
| White Matter | 2 | 2020 | 182 | 0.720 |
Why?
|
| Fibroblasts | 6 | 2019 | 891 | 0.720 |
Why?
|
| Tremor | 6 | 2022 | 130 | 0.680 |
Why?
|
| Parkinson Disease | 9 | 2019 | 693 | 0.670 |
Why?
|
| Communication Disorders | 2 | 2017 | 8 | 0.660 |
Why?
|
| Indians, South American | 4 | 2015 | 14 | 0.650 |
Why?
|
| Myelin Sheath | 1 | 2020 | 132 | 0.650 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 7 | 2020 | 72 | 0.640 |
Why?
|
| Genome, Human | 5 | 2015 | 1273 | 0.630 |
Why?
|
| Oligonucleotides | 2 | 2019 | 89 | 0.630 |
Why?
|
| Nervous System Diseases | 3 | 2017 | 376 | 0.620 |
Why?
|
| Multicenter Studies as Topic | 2 | 2018 | 276 | 0.610 |
Why?
|
| Myasthenia Gravis | 11 | 2000 | 73 | 0.600 |
Why?
|
| Liposomes | 1 | 2019 | 170 | 0.600 |
Why?
|
| DNA Repair Enzymes | 4 | 2020 | 40 | 0.560 |
Why?
|
| Emotions | 2 | 2017 | 364 | 0.550 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2017 | 29 | 0.550 |
Why?
|
| Base Sequence | 21 | 2017 | 3099 | 0.540 |
Why?
|
| Metalloendopeptidases | 1 | 2017 | 100 | 0.540 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 124 | 0.540 |
Why?
|
| Polymerase Chain Reaction | 23 | 2015 | 1587 | 0.540 |
Why?
|
| DNA Mutational Analysis | 13 | 2019 | 791 | 0.520 |
Why?
|
| Severity of Illness Index | 18 | 2025 | 2903 | 0.510 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 2625 | 0.510 |
Why?
|
| Receptors, Cholinergic | 11 | 2002 | 85 | 0.490 |
Why?
|
| Motor Neurons | 3 | 2012 | 142 | 0.480 |
Why?
|
| Gait | 3 | 2020 | 146 | 0.480 |
Why?
|
| Myotonic Disorders | 2 | 2013 | 2 | 0.480 |
Why?
|
| Myotonin-Protein Kinase | 13 | 2023 | 44 | 0.470 |
Why?
|
| Chromosomes, Human, Pair 22 | 5 | 2003 | 103 | 0.470 |
Why?
|
| Aged | 58 | 2025 | 19691 | 0.460 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 75 | 0.460 |
Why?
|
| Molecular Sequence Data | 29 | 2015 | 3881 | 0.460 |
Why?
|
| Indians, Central American | 1 | 2013 | 3 | 0.450 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1929 | 0.440 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 246 | 0.440 |
Why?
|
| Lymphocytes | 7 | 2018 | 407 | 0.440 |
Why?
|
| Brain | 11 | 2020 | 3010 | 0.430 |
Why?
|
| Dermis | 1 | 2013 | 24 | 0.420 |
Why?
|
| Genes, Dominant | 7 | 2013 | 247 | 0.420 |
Why?
|
| Nuclear Proteins | 4 | 2015 | 1272 | 0.420 |
Why?
|
| Chromosome Mapping | 11 | 2015 | 1082 | 0.410 |
Why?
|
| Myotonia Congenita | 4 | 2008 | 5 | 0.410 |
Why?
|
| Cell Line | 12 | 2020 | 2771 | 0.400 |
Why?
|
| Eye Movements | 1 | 2012 | 69 | 0.390 |
Why?
|
| RNA-Binding Proteins | 6 | 2018 | 577 | 0.390 |
Why?
|
| Chloride Channels | 4 | 2008 | 63 | 0.390 |
Why?
|
| Mexico | 11 | 2025 | 180 | 0.380 |
Why?
|
| Animals | 46 | 2024 | 34186 | 0.370 |
Why?
|
| Introns | 6 | 2021 | 301 | 0.370 |
Why?
|
| Seizures | 3 | 2025 | 879 | 0.370 |
Why?
|
| Neurogenesis | 1 | 2012 | 190 | 0.360 |
Why?
|
| Point Mutation | 4 | 2012 | 348 | 0.350 |
Why?
|
| Motor Activity | 3 | 2016 | 523 | 0.350 |
Why?
|
| Neurology | 2 | 2003 | 108 | 0.340 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2018 | 147 | 0.330 |
Why?
|
| Migraine Disorders | 2 | 2010 | 64 | 0.330 |
Why?
|
| Shaw Potassium Channels | 3 | 2013 | 8 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 3587 | 0.320 |
Why?
|
| Dystonia | 3 | 2017 | 172 | 0.320 |
Why?
|
| Alternative Splicing | 4 | 2020 | 350 | 0.310 |
Why?
|
| Genetic Therapy | 4 | 2024 | 683 | 0.310 |
Why?
|
| Genes, Recessive | 4 | 2013 | 179 | 0.310 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2013 | 150 | 0.300 |
Why?
|
| Neoplasms | 2 | 2020 | 2788 | 0.300 |
Why?
|
| Ataxin-2 | 3 | 2020 | 8 | 0.300 |
Why?
|
| Cohort Studies | 13 | 2024 | 4783 | 0.290 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 252 | 0.290 |
Why?
|
| Protein Kinases | 4 | 1997 | 334 | 0.290 |
Why?
|
| Gene Expression | 6 | 2017 | 1570 | 0.290 |
Why?
|
| Carrier Proteins | 2 | 2011 | 1026 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 3142 | 0.290 |
Why?
|
| Tourette Syndrome | 2 | 2003 | 155 | 0.290 |
Why?
|
| Receptors, Nicotinic | 5 | 1994 | 155 | 0.290 |
Why?
|
| Mitosis | 2 | 2015 | 237 | 0.290 |
Why?
|
| Young Adult | 16 | 2025 | 8987 | 0.290 |
Why?
|
| Basal Ganglia Diseases | 1 | 2007 | 27 | 0.280 |
Why?
|
| Iron-Binding Proteins | 8 | 2012 | 32 | 0.280 |
Why?
|
| Aged, 80 and over | 16 | 2020 | 6521 | 0.270 |
Why?
|
| Cells, Cultured | 10 | 2017 | 3061 | 0.270 |
Why?
|
| Depression | 5 | 2024 | 1244 | 0.270 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2006 | 31 | 0.260 |
Why?
|
| Depressive Disorder | 1 | 2010 | 456 | 0.260 |
Why?
|
| Cerebellar Diseases | 3 | 2018 | 75 | 0.260 |
Why?
|
| Neurites | 1 | 2006 | 42 | 0.260 |
Why?
|
| Olfaction Disorders | 2 | 2019 | 28 | 0.260 |
Why?
|
| Ataxins | 3 | 2017 | 114 | 0.250 |
Why?
|
| Longitudinal Studies | 5 | 2024 | 1327 | 0.250 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2005 | 18 | 0.250 |
Why?
|
| Genetic Linkage | 10 | 2013 | 453 | 0.250 |
Why?
|
| Genetic Variation | 5 | 2017 | 1493 | 0.250 |
Why?
|
| Peptide Fragments | 9 | 2019 | 779 | 0.240 |
Why?
|
| Genetic Counseling | 4 | 2002 | 221 | 0.240 |
Why?
|
| Prospective Studies | 7 | 2023 | 6137 | 0.240 |
Why?
|
| Pyramidal Tracts | 2 | 2020 | 36 | 0.240 |
Why?
|
| Mice | 21 | 2021 | 17748 | 0.240 |
Why?
|
| Muscles | 10 | 2020 | 289 | 0.240 |
Why?
|
| Fatigue | 2 | 2024 | 194 | 0.240 |
Why?
|
| Family Health | 8 | 2013 | 259 | 0.230 |
Why?
|
| DNA, Mitochondrial | 3 | 2010 | 211 | 0.230 |
Why?
|
| Adolescent | 32 | 2025 | 19329 | 0.230 |
Why?
|
| Cognitive Dysfunction | 2 | 2021 | 233 | 0.230 |
Why?
|
| Quality of Life | 3 | 2024 | 1948 | 0.230 |
Why?
|
| Activities of Daily Living | 3 | 2022 | 404 | 0.220 |
Why?
|
| Isoenzymes | 3 | 2001 | 228 | 0.220 |
Why?
|
| Comorbidity | 5 | 2020 | 1531 | 0.220 |
Why?
|
| Essential Tremor | 3 | 2004 | 89 | 0.220 |
Why?
|
| Spermatozoa | 4 | 2004 | 224 | 0.220 |
Why?
|
| Mexican Americans | 2 | 2002 | 204 | 0.220 |
Why?
|
| Peru | 2 | 2021 | 47 | 0.210 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 170 | 0.210 |
Why?
|
| Case-Control Studies | 10 | 2020 | 3287 | 0.210 |
Why?
|
| HEK293 Cells | 3 | 2021 | 753 | 0.210 |
Why?
|
| Stem Cell Transplantation | 2 | 2016 | 236 | 0.210 |
Why?
|
| Biomarkers | 5 | 2023 | 3063 | 0.200 |
Why?
|
| Chorea | 4 | 2004 | 39 | 0.200 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2023 | 80 | 0.200 |
Why?
|
| Founder Effect | 2 | 2020 | 31 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2021 | 238 | 0.200 |
Why?
|
| Amino Acid Sequence | 15 | 2011 | 2704 | 0.190 |
Why?
|
| Membrane Glycoproteins | 2 | 2023 | 412 | 0.190 |
Why?
|
| Ubiquinone | 2 | 2014 | 25 | 0.190 |
Why?
|
| Kearns-Sayre Syndrome | 1 | 2001 | 6 | 0.190 |
Why?
|
| Transcription, Genetic | 5 | 2019 | 1704 | 0.190 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2003 | 213 | 0.190 |
Why?
|
| RNA, Messenger | 7 | 2023 | 2825 | 0.190 |
Why?
|
| Nucleic Acid Conformation | 2 | 2017 | 184 | 0.180 |
Why?
|
| Huntingtin Protein | 2 | 2019 | 63 | 0.180 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2021 | 24 | 0.180 |
Why?
|
| Mice, Inbred ICR | 2 | 2019 | 153 | 0.180 |
Why?
|
| Autoantibodies | 5 | 2000 | 436 | 0.180 |
Why?
|
| Genomic Instability | 3 | 2013 | 229 | 0.180 |
Why?
|
| Stereotaxic Techniques | 1 | 2021 | 70 | 0.180 |
Why?
|
| Replication Protein C | 1 | 2020 | 6 | 0.180 |
Why?
|
| Genetic Techniques | 2 | 2001 | 106 | 0.180 |
Why?
|
| Pregnancy Complications | 3 | 2018 | 507 | 0.180 |
Why?
|
| Mutant Proteins | 2 | 2019 | 112 | 0.180 |
Why?
|
| Multiple System Atrophy | 1 | 2020 | 17 | 0.180 |
Why?
|
| Fragile X Syndrome | 1 | 2022 | 150 | 0.180 |
Why?
|
| Transfection | 3 | 2018 | 1069 | 0.180 |
Why?
|
| 3' Untranslated Regions | 3 | 2018 | 165 | 0.170 |
Why?
|
| C9orf72 Protein | 2 | 2017 | 24 | 0.170 |
Why?
|
| Electrophoresis, Capillary | 1 | 2020 | 12 | 0.170 |
Why?
|
| DNA Repair | 3 | 2019 | 587 | 0.170 |
Why?
|
| DNA End-Joining Repair | 1 | 2020 | 34 | 0.170 |
Why?
|
| Mitomycin | 4 | 2015 | 49 | 0.170 |
Why?
|
| Muscular Dystrophies | 3 | 2013 | 51 | 0.170 |
Why?
|
| RNA Polymerase II | 1 | 2020 | 100 | 0.170 |
Why?
|
| Rett Syndrome | 1 | 2003 | 291 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2025 | 3448 | 0.160 |
Why?
|
| RNA Splicing | 3 | 2018 | 226 | 0.160 |
Why?
|
| Postural Balance | 1 | 2020 | 125 | 0.160 |
Why?
|
| Codon, Terminator | 2 | 2012 | 26 | 0.160 |
Why?
|
| Membrane Transport Proteins | 1 | 2000 | 177 | 0.160 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 2410 | 0.160 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 237 | 0.160 |
Why?
|
| Genetic Markers | 7 | 2020 | 606 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 1998 | 1664 | 0.160 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2018 | 8 | 0.160 |
Why?
|
| Anticipation, Genetic | 4 | 2013 | 4 | 0.160 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 2059 | 0.160 |
Why?
|
| Scoliosis | 1 | 2020 | 135 | 0.150 |
Why?
|
| Brain Diseases | 2 | 1998 | 301 | 0.150 |
Why?
|
| Microvessels | 1 | 2019 | 55 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 515 | 0.150 |
Why?
|
| Minisatellite Repeats | 2 | 1995 | 43 | 0.150 |
Why?
|
| Proteins | 4 | 2021 | 1046 | 0.150 |
Why?
|
| Receptors, LDL | 1 | 2019 | 89 | 0.150 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 238 | 0.150 |
Why?
|
| Epitopes | 5 | 1994 | 431 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 143 | 0.150 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2018 | 13 | 0.150 |
Why?
|
| Acridines | 1 | 1998 | 7 | 0.150 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 130 | 0.150 |
Why?
|
| Curriculum | 1 | 2003 | 723 | 0.150 |
Why?
|
| Blindness | 1 | 1998 | 72 | 0.140 |
Why?
|
| Smell | 1 | 2019 | 120 | 0.140 |
Why?
|
| Frontotemporal Dementia | 1 | 2018 | 43 | 0.140 |
Why?
|
| Deafness | 1 | 1998 | 83 | 0.140 |
Why?
|
| ran GTP-Binding Protein | 1 | 2017 | 28 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2024 | 842 | 0.140 |
Why?
|
| Cell Nucleus | 3 | 2016 | 677 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 5 | 2013 | 1761 | 0.140 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2017 | 67 | 0.140 |
Why?
|
| Receptors, Dopamine | 2 | 2013 | 40 | 0.140 |
Why?
|
| Polysomnography | 1 | 2018 | 143 | 0.140 |
Why?
|
| RNA, Antisense | 1 | 2017 | 35 | 0.140 |
Why?
|
| Calcium Channels | 3 | 2007 | 159 | 0.140 |
Why?
|
| Protein Binding | 5 | 2019 | 1749 | 0.140 |
Why?
|
| Rats | 10 | 2011 | 3689 | 0.140 |
Why?
|
| Psychoses, Substance-Induced | 1 | 1996 | 9 | 0.140 |
Why?
|
| Child | 24 | 2014 | 24454 | 0.140 |
Why?
|
| China | 4 | 2021 | 245 | 0.140 |
Why?
|
| Genetic Association Studies | 4 | 2013 | 777 | 0.130 |
Why?
|
| Neck Muscles | 1 | 1996 | 12 | 0.130 |
Why?
|
| Solvents | 1 | 1996 | 43 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 764 | 0.130 |
Why?
|
| Ceruletide | 1 | 1996 | 2 | 0.130 |
Why?
|
| Fluphenazine | 1 | 1996 | 5 | 0.130 |
Why?
|
| Sensorimotor Cortex | 1 | 2016 | 7 | 0.130 |
Why?
|
| Retina | 2 | 2017 | 453 | 0.130 |
Why?
|
| Mitomycins | 2 | 1995 | 10 | 0.130 |
Why?
|
| Latin America | 2 | 2013 | 89 | 0.130 |
Why?
|
| Adenylyl Cyclases | 1 | 1996 | 83 | 0.130 |
Why?
|
| Cell Line, Transformed | 2 | 2012 | 169 | 0.130 |
Why?
|
| Channelopathies | 1 | 2016 | 11 | 0.130 |
Why?
|
| Dopamine Antagonists | 1 | 1996 | 50 | 0.130 |
Why?
|
| Corpus Striatum | 1 | 1996 | 91 | 0.130 |
Why?
|
| Neurologic Examination | 7 | 2012 | 195 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2018 | 169 | 0.130 |
Why?
|
| Ataxia Telangiectasia | 1 | 2015 | 15 | 0.120 |
Why?
|
| Affect | 2 | 2012 | 159 | 0.120 |
Why?
|
| DNA Damage | 3 | 2015 | 515 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 107 | 0.120 |
Why?
|
| Pyrazoles | 1 | 1998 | 307 | 0.120 |
Why?
|
| Body Composition | 1 | 2018 | 524 | 0.120 |
Why?
|
| Leukocytes | 4 | 2004 | 206 | 0.120 |
Why?
|
| Endothelial Cells | 1 | 2019 | 526 | 0.120 |
Why?
|
| Muscle, Skeletal | 3 | 2018 | 954 | 0.120 |
Why?
|
| Protein Kinase C-delta | 2 | 2015 | 17 | 0.120 |
Why?
|
| Tomography, Optical Coherence | 2 | 2017 | 523 | 0.120 |
Why?
|
| Ocular Motility Disorders | 1 | 2015 | 38 | 0.120 |
Why?
|
| Italy | 3 | 2014 | 113 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 19 | 6 | 1996 | 59 | 0.110 |
Why?
|
| Protein Biosynthesis | 1 | 2017 | 665 | 0.110 |
Why?
|
| Hot Temperature | 2 | 1985 | 136 | 0.110 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 3341 | 0.110 |
Why?
|
| Blotting, Southern | 5 | 2006 | 215 | 0.110 |
Why?
|
| Atrophy | 2 | 2013 | 236 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2012 | 57 | 0.110 |
Why?
|
| Sound Localization | 1 | 2013 | 1 | 0.110 |
Why?
|
| Genetics, Population | 4 | 2013 | 187 | 0.110 |
Why?
|
| Histidine | 1 | 2013 | 72 | 0.110 |
Why?
|
| Indians, North American | 1 | 2013 | 59 | 0.110 |
Why?
|
| Antibodies | 3 | 1994 | 372 | 0.110 |
Why?
|
| Behavior, Animal | 1 | 1996 | 491 | 0.110 |
Why?
|
| Prevalence | 5 | 2024 | 2451 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2003 | 1177 | 0.110 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1090 | 0.110 |
Why?
|
| Immunoglobulins | 2 | 1985 | 171 | 0.100 |
Why?
|
| Genomics | 1 | 2021 | 1491 | 0.100 |
Why?
|
| Suicidal Ideation | 1 | 2015 | 218 | 0.100 |
Why?
|
| Receptors, Dopamine D2 | 3 | 2013 | 45 | 0.100 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2012 | 42 | 0.100 |
Why?
|
| Protein Conformation | 2 | 1994 | 833 | 0.100 |
Why?
|
| Receptors, Kainic Acid | 1 | 2012 | 5 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2013 | 91 | 0.100 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2012 | 58 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2015 | 615 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 580 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2018 | 1004 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2012 | 109 | 0.100 |
Why?
|
| Olfactory Perception | 1 | 2012 | 27 | 0.100 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2013 | 149 | 0.100 |
Why?
|
| Twins, Monozygotic | 1 | 1992 | 117 | 0.100 |
Why?
|
| Substance-Related Disorders | 1 | 1996 | 459 | 0.100 |
Why?
|
| Membrane Proteins | 3 | 2011 | 1527 | 0.100 |
Why?
|
| Diseases in Twins | 1 | 1992 | 94 | 0.100 |
Why?
|
| alpha-Synuclein | 2 | 2006 | 123 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 1994 | 319 | 0.100 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2012 | 106 | 0.100 |
Why?
|
| Cell Survival | 3 | 2017 | 807 | 0.100 |
Why?
|
| Alcoholic Beverages | 1 | 2011 | 18 | 0.100 |
Why?
|
| Argentina | 2 | 2011 | 52 | 0.090 |
Why?
|
| Monitoring, Ambulatory | 1 | 2011 | 54 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 197 | 0.090 |
Why?
|
| Linkage Disequilibrium | 2 | 2003 | 309 | 0.090 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 195 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 1189 | 0.090 |
Why?
|
| Mitochondria | 3 | 2014 | 692 | 0.090 |
Why?
|
| Arginine | 1 | 2013 | 330 | 0.090 |
Why?
|
| Vision Disorders | 1 | 2013 | 212 | 0.090 |
Why?
|
| Cellular Reprogramming | 1 | 2012 | 116 | 0.090 |
Why?
|
| Home Care Services | 1 | 2011 | 69 | 0.090 |
Why?
|
| Multiple Sclerosis | 2 | 1985 | 338 | 0.090 |
Why?
|
| Family | 1 | 2014 | 565 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2022 | 2880 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2002 | 84 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2011 | 138 | 0.090 |
Why?
|
| TATA-Box Binding Protein | 2 | 2007 | 30 | 0.090 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein K | 1 | 2010 | 8 | 0.090 |
Why?
|
| Serine | 1 | 2011 | 173 | 0.090 |
Why?
|
| Models, Genetic | 2 | 2020 | 759 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 7 | 2002 | 4430 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 1998 | 1066 | 0.090 |
Why?
|
| Glycine | 1 | 2011 | 167 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 519 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 869 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2013 | 385 | 0.080 |
Why?
|
| Electroencephalography | 5 | 2021 | 869 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2025 | 16299 | 0.080 |
Why?
|
| Synucleins | 2 | 2000 | 13 | 0.080 |
Why?
|
| Parents | 2 | 1994 | 1029 | 0.080 |
Why?
|
| Gene Editing | 2 | 2024 | 194 | 0.080 |
Why?
|
| Cataract | 1 | 1992 | 221 | 0.080 |
Why?
|
| United States | 6 | 2015 | 10886 | 0.080 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 344 | 0.080 |
Why?
|
| Complement System Proteins | 2 | 1985 | 58 | 0.080 |
Why?
|
| Liver Neoplasms | 5 | 2000 | 1319 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 5 | 2000 | 1008 | 0.080 |
Why?
|
| Exome | 1 | 2013 | 1042 | 0.070 |
Why?
|
| COS Cells | 2 | 2006 | 276 | 0.070 |
Why?
|
| Skin Absorption | 1 | 1987 | 7 | 0.070 |
Why?
|
| Flurbiprofen | 1 | 1987 | 5 | 0.070 |
Why?
|
| Skin Temperature | 1 | 1987 | 19 | 0.070 |
Why?
|
| Psychological Tests | 3 | 2001 | 93 | 0.070 |
Why?
|
| Penetrance | 3 | 2021 | 103 | 0.070 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1995 | 143 | 0.070 |
Why?
|
| Propionates | 1 | 1987 | 30 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2012 | 2610 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2004 | 333 | 0.070 |
Why?
|
| HeLa Cells | 3 | 2018 | 809 | 0.070 |
Why?
|
| Self Medication | 1 | 2007 | 23 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2305 | 0.070 |
Why?
|
| Apoptosis | 2 | 2015 | 1791 | 0.070 |
Why?
|
| Receptors, Dopamine D4 | 2 | 2013 | 4 | 0.070 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4356 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2013 | 25 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2003 | 1894 | 0.070 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2013 | 34 | 0.070 |
Why?
|
| Sarcoma 180 | 2 | 1998 | 2 | 0.070 |
Why?
|
| Nonprescription Drugs | 1 | 2007 | 50 | 0.070 |
Why?
|
| Basal Ganglia | 1 | 2007 | 56 | 0.070 |
Why?
|
| Genetic Carrier Screening | 2 | 2004 | 68 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2018 | 1291 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2018 | 427 | 0.070 |
Why?
|
| Neuromuscular Junction | 2 | 1985 | 92 | 0.070 |
Why?
|
| Muscle Spasticity | 2 | 2013 | 73 | 0.070 |
Why?
|
| Hemiplegia | 1 | 1986 | 42 | 0.070 |
Why?
|
| Genes, Plant | 1 | 2006 | 28 | 0.070 |
Why?
|
| Heterozygote | 2 | 2020 | 676 | 0.070 |
Why?
|
| Child, Preschool | 11 | 2013 | 14050 | 0.070 |
Why?
|
| Gait Ataxia | 1 | 2006 | 6 | 0.070 |
Why?
|
| Plant Diseases | 1 | 2006 | 20 | 0.070 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2006 | 8 | 0.070 |
Why?
|
| PC12 Cells | 1 | 2006 | 26 | 0.070 |
Why?
|
| Oryza | 1 | 2006 | 24 | 0.070 |
Why?
|
| Nerve Growth Factor | 1 | 2006 | 24 | 0.070 |
Why?
|
| Health Status | 1 | 2008 | 374 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 388 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2006 | 142 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2011 | 150 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2023 | 12342 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 143 | 0.060 |
Why?
|
| Evoked Potentials, Visual | 1 | 1985 | 33 | 0.060 |
Why?
|
| ras Proteins | 1 | 2006 | 137 | 0.060 |
Why?
|
| Physical Examination | 1 | 2006 | 162 | 0.060 |
Why?
|
| Carbachol | 2 | 1982 | 18 | 0.060 |
Why?
|
| Motor Endplate | 1 | 1985 | 15 | 0.060 |
Why?
|
| Antioxidants | 1 | 2007 | 336 | 0.060 |
Why?
|
| T-Lymphocytes | 5 | 2002 | 1708 | 0.060 |
Why?
|
| Carbamazepine | 2 | 2021 | 48 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2015 | 4542 | 0.060 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 3726 | 0.060 |
Why?
|
| Mosaicism | 2 | 1997 | 241 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 316 | 0.060 |
Why?
|
| Electromyography | 2 | 2013 | 165 | 0.060 |
Why?
|
| Minocycline | 1 | 2004 | 36 | 0.060 |
Why?
|
| Age Factors | 5 | 2007 | 2817 | 0.060 |
Why?
|
| Glycogen Phosphorylase, Muscle Form | 1 | 2003 | 1 | 0.060 |
Why?
|
| Immersion | 1 | 1983 | 8 | 0.060 |
Why?
|
| Gallium Radioisotopes | 1 | 1983 | 5 | 0.060 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 52 | 0.060 |
Why?
|
| Glycogen Storage Disease Type V | 1 | 2003 | 2 | 0.060 |
Why?
|
| Acanthocytes | 1 | 2003 | 1 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1636 | 0.060 |
Why?
|
| Brain Stem | 2 | 2020 | 116 | 0.050 |
Why?
|
| Specialty Boards | 1 | 2003 | 19 | 0.050 |
Why?
|
| Quantitative Trait Loci | 3 | 2013 | 284 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2020 | 315 | 0.050 |
Why?
|
| Homozygote | 2 | 2002 | 534 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 1986 | 457 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2020 | 1019 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 926 | 0.050 |
Why?
|
| History, 20th Century | 3 | 2015 | 384 | 0.050 |
Why?
|
| Accreditation | 1 | 2003 | 87 | 0.050 |
Why?
|
| Time Factors | 4 | 2013 | 6309 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2004 | 86 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2023 | 36 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 415 | 0.050 |
Why?
|
| Ataxin-7 | 2 | 1999 | 14 | 0.050 |
Why?
|
| Executive Function | 1 | 2024 | 105 | 0.050 |
Why?
|
| Neural Pathways | 2 | 2016 | 267 | 0.050 |
Why?
|
| DNA, Superhelical | 1 | 2003 | 20 | 0.050 |
Why?
|
| Germ Cells | 1 | 2004 | 195 | 0.050 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 211 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2003 | 118 | 0.050 |
Why?
|
| Cognition Disorders | 2 | 2024 | 554 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2004 | 136 | 0.050 |
Why?
|
| Epilepsy, Complex Partial | 1 | 2002 | 13 | 0.050 |
Why?
|
| Base Composition | 2 | 2018 | 71 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2022 | 290 | 0.050 |
Why?
|
| Spasms, Infantile | 2 | 2004 | 171 | 0.050 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2002 | 56 | 0.050 |
Why?
|
| Syndrome | 3 | 1998 | 1118 | 0.050 |
Why?
|
| Myasthenia Gravis, Autoimmune, Experimental | 1 | 2002 | 6 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 64 | 0.050 |
Why?
|
| Torpedo | 4 | 2002 | 37 | 0.050 |
Why?
|
| Doxorubicin | 3 | 2004 | 297 | 0.050 |
Why?
|
| Myocytes, Cardiac | 2 | 2018 | 623 | 0.050 |
Why?
|
| Spain | 1 | 2002 | 61 | 0.050 |
Why?
|
| Epilepsy, Benign Neonatal | 1 | 2001 | 13 | 0.050 |
Why?
|
| Computers | 1 | 2022 | 68 | 0.050 |
Why?
|
| Anticonvulsants | 2 | 2021 | 381 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2021 | 7 | 0.050 |
Why?
|
| Plasmids | 1 | 2003 | 514 | 0.050 |
Why?
|
| Eye Abnormalities | 2 | 2013 | 106 | 0.050 |
Why?
|
| Antibody Formation | 4 | 2002 | 264 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 782 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1987 | 234 | 0.050 |
Why?
|
| Canada | 1 | 2002 | 300 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2023 | 299 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 82 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 96 | 0.040 |
Why?
|
| RNA, Transfer, Glu | 1 | 2000 | 2 | 0.040 |
Why?
|
| Monoamine Oxidase | 1 | 2000 | 11 | 0.040 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2000 | 8 | 0.040 |
Why?
|
| Cyclins | 1 | 2001 | 101 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2006 | 770 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 113 | 0.040 |
Why?
|
| Ribonucleoproteins | 1 | 2000 | 62 | 0.040 |
Why?
|
| Epileptic Syndromes | 1 | 2021 | 30 | 0.040 |
Why?
|
| Cuba | 1 | 2020 | 6 | 0.040 |
Why?
|
| Mandibular Diseases | 1 | 1980 | 9 | 0.040 |
Why?
|
| Synaptic Transmission | 3 | 2012 | 350 | 0.040 |
Why?
|
| Facial Muscles | 1 | 1980 | 33 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2020 | 16 | 0.040 |
Why?
|
| Infant, Newborn | 5 | 2013 | 8182 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 31 | 0.040 |
Why?
|
| Biostatistics | 1 | 2020 | 10 | 0.040 |
Why?
|
| Poly A | 2 | 2016 | 59 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2000 | 103 | 0.040 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2003 | 309 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2000 | 25 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2000 | 25 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 207 | 0.040 |
Why?
|
| Eyelid Diseases | 1 | 1980 | 73 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 2000 | 153 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 70 | 0.040 |
Why?
|
| Blepharospasm | 1 | 1980 | 49 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 712 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2000 | 126 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2000 | 187 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2001 | 626 | 0.040 |
Why?
|
| Polyadenylation | 1 | 2020 | 55 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 1986 | 2090 | 0.040 |
Why?
|
| Carcinoma, Giant Cell | 1 | 1999 | 2 | 0.040 |
Why?
|
| Protons | 1 | 1999 | 91 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2002 | 692 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 620 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2019 | 48 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2011 | 1075 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2000 | 160 | 0.040 |
Why?
|
| Greece | 1 | 1998 | 11 | 0.040 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 133 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 354 | 0.040 |
Why?
|
| Ion Channels | 2 | 2014 | 194 | 0.040 |
Why?
|
| RNA 3' Polyadenylation Signals | 1 | 2018 | 1 | 0.040 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2019 | 121 | 0.040 |
Why?
|
| Walking | 2 | 2011 | 214 | 0.040 |
Why?
|
| Liver Diseases | 1 | 1982 | 366 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 1163 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2019 | 129 | 0.040 |
Why?
|
| Patient Selection | 2 | 2016 | 693 | 0.040 |
Why?
|
| Mice, Nude | 2 | 1998 | 710 | 0.040 |
Why?
|
| Mice, Inbred DBA | 2 | 1995 | 48 | 0.040 |
Why?
|
| Chromosome Segregation | 2 | 2011 | 63 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2044 | 0.040 |
Why?
|
| Software | 1 | 2023 | 686 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2008 | 70 | 0.040 |
Why?
|
| Fibrosarcoma | 1 | 1998 | 27 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1998 | 49 | 0.040 |
Why?
|
| Nurses | 1 | 1998 | 67 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 1983 | 938 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 2018 | 46 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 137 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 670 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2018 | 117 | 0.040 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 1998 | 44 | 0.040 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 43 | 0.040 |
Why?
|
| Restless Legs Syndrome | 1 | 2017 | 19 | 0.040 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2017 | 16 | 0.040 |
Why?
|
| Anthropometry | 1 | 2018 | 198 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 1998 | 255 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 242 | 0.040 |
Why?
|
| Molecular Structure | 1 | 1998 | 290 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2000 | 302 | 0.030 |
Why?
|
| Exons | 2 | 2013 | 796 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1998 | 79 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 731 | 0.030 |
Why?
|
| Health Status Indicators | 2 | 2008 | 121 | 0.030 |
Why?
|
| Cloning, Molecular | 3 | 2011 | 892 | 0.030 |
Why?
|
| Spiperone | 1 | 1996 | 1 | 0.030 |
Why?
|
| Transcription Activator-Like Effector Nucleases | 1 | 2016 | 3 | 0.030 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 1998 | 199 | 0.030 |
Why?
|
| Alcoholism | 1 | 1998 | 231 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2015 | 807 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 435 | 0.030 |
Why?
|
| Hand Strength | 1 | 2016 | 40 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2017 | 142 | 0.030 |
Why?
|
| Cell Membrane | 3 | 1994 | 463 | 0.030 |
Why?
|
| Disability Evaluation | 2 | 2008 | 193 | 0.030 |
Why?
|
| Clone Cells | 1 | 1996 | 168 | 0.030 |
Why?
|
| Leukemia P388 | 1 | 1995 | 2 | 0.030 |
Why?
|
| Lethal Dose 50 | 1 | 1995 | 17 | 0.030 |
Why?
|
| Benzazepines | 1 | 1996 | 65 | 0.030 |
Why?
|
| Biotransformation | 1 | 1995 | 50 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 1995 | 29 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 262 | 0.030 |
Why?
|
| Maps as Topic | 1 | 2015 | 1 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 1994 | 202 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 43 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2017 | 129 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2016 | 72 | 0.030 |
Why?
|
| Torticollis | 1 | 1996 | 72 | 0.030 |
Why?
|
| Receptors, Dopamine D1 | 1 | 1996 | 85 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 298 | 0.030 |
Why?
|
| Arm | 2 | 2005 | 81 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1996 | 254 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 80 | 0.030 |
Why?
|
| Gene Targeting | 1 | 2016 | 179 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 314 | 0.030 |
Why?
|
| Pregnancy | 3 | 2018 | 7172 | 0.030 |
Why?
|
| PubMed | 1 | 2015 | 20 | 0.030 |
Why?
|
| Nigeria | 1 | 1995 | 79 | 0.030 |
Why?
|
| Immunoassay | 1 | 2015 | 130 | 0.030 |
Why?
|
| Drosophila | 1 | 2020 | 781 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1690 | 0.030 |
Why?
|
| Bolivia | 1 | 2015 | 14 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1996 | 360 | 0.030 |
Why?
|
| Voice | 1 | 1995 | 14 | 0.030 |
Why?
|
| Teratoma | 1 | 2016 | 123 | 0.030 |
Why?
|
| Leg | 2 | 2005 | 160 | 0.030 |
Why?
|
| Protein Aggregates | 1 | 2015 | 29 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 1265 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 1998 | 2509 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 95 | 0.030 |
Why?
|
| Dopamine | 1 | 1996 | 286 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2016 | 339 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2000 | 1017 | 0.030 |
Why?
|
| Infant | 6 | 2013 | 12483 | 0.030 |
Why?
|
| Immunization | 3 | 1994 | 307 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1994 | 60 | 0.030 |
Why?
|
| Sequence Alignment | 2 | 2011 | 626 | 0.030 |
Why?
|
| Philippines | 1 | 2013 | 23 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 269 | 0.030 |
Why?
|
| Drug Stability | 1 | 1993 | 57 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2016 | 399 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 85 | 0.030 |
Why?
|
| Auditory Threshold | 1 | 2013 | 17 | 0.030 |
Why?
|
| Blood Cells | 1 | 1993 | 49 | 0.030 |
Why?
|
| Microscopy, Atomic Force | 2 | 2004 | 14 | 0.030 |
Why?
|
| CELF1 Protein | 2 | 2006 | 48 | 0.030 |
Why?
|
| Mammals | 1 | 2015 | 260 | 0.030 |
Why?
|
| Neuroacanthocytosis | 1 | 2013 | 1 | 0.030 |
Why?
|
| Fetal Diseases | 1 | 1997 | 446 | 0.030 |
Why?
|
| Attitude to Health | 1 | 1995 | 257 | 0.030 |
Why?
|
| Gestational Age | 1 | 1997 | 1161 | 0.030 |
Why?
|
| Hearing | 1 | 2013 | 52 | 0.030 |
Why?
|
| Telangiectasis | 1 | 2013 | 8 | 0.030 |
Why?
|
| Myopathies, Nemaline | 1 | 2013 | 8 | 0.030 |
Why?
|
| Fathers | 1 | 1994 | 68 | 0.030 |
Why?
|
| Cues | 1 | 2013 | 90 | 0.030 |
Why?
|
| Contrast Sensitivity | 1 | 2013 | 59 | 0.030 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2013 | 7 | 0.030 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2013 | 39 | 0.030 |
Why?
|
| Pyridostigmine Bromide | 1 | 1992 | 13 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 1999 | 687 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 107 | 0.030 |
Why?
|
| Optic Atrophy | 1 | 2013 | 47 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1237 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 619 | 0.030 |
Why?
|
| Myocardium | 1 | 2018 | 1008 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1810 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 400 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2013 | 412 | 0.030 |
Why?
|
| Facial Expression | 1 | 2012 | 28 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2012 | 40 | 0.030 |
Why?
|
| Enzootic Bovine Leukosis | 1 | 1992 | 1 | 0.020 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 1992 | 14 | 0.020 |
Why?
|
| Synaptosomal-Associated Protein 25 | 1 | 2011 | 12 | 0.020 |
Why?
|
| Chi-Square Distribution | 2 | 2005 | 585 | 0.020 |
Why?
|
| Prednisone | 1 | 1992 | 275 | 0.020 |
Why?
|
| Prognosis | 2 | 2015 | 4607 | 0.020 |
Why?
|
| Paralysis | 1 | 1992 | 35 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 1995 | 451 | 0.020 |
Why?
|
| Nucleotides, Cyclic | 2 | 1982 | 6 | 0.020 |
Why?
|
| Carbazoles | 1 | 1992 | 33 | 0.020 |
Why?
|
| Japan | 2 | 2004 | 133 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 125 | 0.020 |
Why?
|
| Hepatic Artery | 2 | 2000 | 51 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1992 | 256 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 757 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 2 | 2008 | 120 | 0.020 |
Why?
|
| Venezuela | 1 | 2011 | 13 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 354 | 0.020 |
Why?
|
| Oculomotor Muscles | 1 | 1992 | 63 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2011 | 35 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 1992 | 150 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1691 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2011 | 37 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 1992 | 144 | 0.020 |
Why?
|
| Blepharoptosis | 1 | 1992 | 67 | 0.020 |
Why?
|
| Molecular Biology | 2 | 2004 | 79 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 223 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 550 | 0.020 |
Why?
|
| Mothers | 1 | 1994 | 354 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 1624 | 0.020 |
Why?
|
| Autophagy | 1 | 2014 | 395 | 0.020 |
Why?
|
| Indoles | 1 | 1992 | 181 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1995 | 494 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2012 | 257 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 1982 | 776 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2006 | 153 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 421 | 0.020 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2011 | 92 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2017 | 824 | 0.020 |
Why?
|
| Spectrin | 1 | 2011 | 63 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2011 | 253 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 675 | 0.020 |
Why?
|
| Sex Factors | 1 | 1994 | 1285 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2012 | 273 | 0.020 |
Why?
|
| Speech Disorders | 1 | 2010 | 43 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 383 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 1109 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2011 | 227 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2011 | 216 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 546 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 369 | 0.020 |
Why?
|
| Guinea Pigs | 3 | 1985 | 167 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1998 | 1547 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1988 | 49 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 276 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1988 | 55 | 0.020 |
Why?
|
| Anxiety | 1 | 1995 | 967 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 2538 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2013 | 824 | 0.020 |
Why?
|
| Costa Rica | 1 | 2008 | 13 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 251 | 0.020 |
Why?
|
| Neurons | 1 | 2018 | 1966 | 0.020 |
Why?
|
| Polychondritis, Relapsing | 1 | 1988 | 5 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 1604 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 426 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2007 | 25 | 0.020 |
Why?
|
| Risk Factors | 2 | 1992 | 10272 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 1987 | 66 | 0.020 |
Why?
|
| Codon | 1 | 2007 | 97 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2000 | 107 | 0.020 |
Why?
|
| Vasculitis | 1 | 1988 | 50 | 0.020 |
Why?
|
| Genes | 1 | 1988 | 445 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2013 | 963 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 2142 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1988 | 122 | 0.020 |
Why?
|
| Reflex, Abnormal | 1 | 1986 | 16 | 0.020 |
Why?
|
| Dinucleotide Repeats | 1 | 2006 | 5 | 0.020 |
Why?
|
| Global Health | 1 | 1991 | 558 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 1422 | 0.020 |
Why?
|
| Chromosomes, Plant | 1 | 2006 | 7 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2004 | 426 | 0.020 |
Why?
|
| Portugal | 1 | 2006 | 7 | 0.020 |
Why?
|
| DNA Primers | 2 | 2000 | 660 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 943 | 0.020 |
Why?
|
| Ascomycota | 1 | 2006 | 26 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 301 | 0.020 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1986 | 18 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 393 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2006 | 260 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 1986 | 144 | 0.020 |
Why?
|
| Thymus Gland | 2 | 1985 | 101 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 1975 | 35 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 658 | 0.020 |
Why?
|
| Muramidase | 2 | 1975 | 93 | 0.020 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1061 | 0.020 |
Why?
|
| Oligoclonal Bands | 1 | 1985 | 2 | 0.020 |
Why?
|
| Baths | 1 | 1985 | 16 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 470 | 0.020 |
Why?
|
| Quinuclidinyl Benzilate | 1 | 1985 | 3 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 179 | 0.020 |
Why?
|
| Receptors, Muscarinic | 1 | 1985 | 14 | 0.020 |
Why?
|
| Quinuclidines | 1 | 1985 | 8 | 0.020 |
Why?
|
| Ethyl Methanesulfonate | 1 | 2004 | 9 | 0.020 |
Why?
|
| Synaptosomes | 1 | 1985 | 31 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1985 | 65 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2004 | 26 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2005 | 85 | 0.010 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1985 | 43 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2004 | 69 | 0.010 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2005 | 46 | 0.010 |
Why?
|
| Eye | 1 | 2006 | 227 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 1674 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 31 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2012 | 3753 | 0.010 |
Why?
|
| Restriction Mapping | 2 | 1996 | 188 | 0.010 |
Why?
|
| AT Rich Sequence | 1 | 2004 | 3 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 98 | 0.010 |
Why?
|
| Observer Variation | 1 | 2005 | 299 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2004 | 96 | 0.010 |
Why?
|
| Fluorescence | 1 | 2004 | 95 | 0.010 |
Why?
|
| North America | 1 | 2004 | 240 | 0.010 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2003 | 1 | 0.010 |
Why?
|
| Hodgkin Disease | 2 | 1986 | 293 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 125 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1985 | 263 | 0.010 |
Why?
|
| Erythrocyte Membrane | 1 | 2003 | 23 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 186 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1995 | 392 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1983 | 151 | 0.010 |
Why?
|
| RNA, Untranslated | 1 | 2004 | 112 | 0.010 |
Why?
|
| Dystonic Disorders | 1 | 2004 | 85 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2006 | 372 | 0.010 |
Why?
|
| Movement | 1 | 2004 | 171 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 315 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 43 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2007 | 868 | 0.010 |
Why?
|
| Base Pairing | 1 | 2003 | 43 | 0.010 |
Why?
|
| Phenytoin | 1 | 1983 | 64 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 489 | 0.010 |
Why?
|
| Cosmids | 2 | 1992 | 48 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 1341 | 0.010 |
Why?
|
| Vesicular Transport Proteins | 1 | 2003 | 120 | 0.010 |
Why?
|
| Thymectomy | 1 | 1982 | 19 | 0.010 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2002 | 33 | 0.010 |
Why?
|
| Bungarotoxins | 1 | 1982 | 15 | 0.010 |
Why?
|
| France | 1 | 2002 | 79 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1982 | 90 | 0.010 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 1982 | 58 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1982 | 204 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 2003 | 312 | 0.010 |
Why?
|
| Fatty Liver | 1 | 1982 | 183 | 0.010 |
Why?
|
| DNA Replication | 1 | 2003 | 351 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2000 | 35 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2003 | 359 | 0.010 |
Why?
|
| Antigens, Fungal | 1 | 2000 | 34 | 0.010 |
Why?
|
| Epirubicin | 1 | 2000 | 5 | 0.010 |
Why?
|
| Cerebellar Cortex | 1 | 2000 | 21 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2000 | 27 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2000 | 40 | 0.010 |
Why?
|
| Lod Score | 1 | 2000 | 120 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 1402 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2000 | 128 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 193 | 0.010 |
Why?
|
| Cell Migration Inhibition | 2 | 1975 | 10 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1999 | 35 | 0.010 |
Why?
|
| Keratins | 1 | 1999 | 55 | 0.010 |
Why?
|
| Hospitals, Special | 1 | 1998 | 14 | 0.010 |
Why?
|
| Genes, ras | 1 | 1999 | 99 | 0.010 |
Why?
|
| Hospitals, General | 1 | 1998 | 24 | 0.010 |
Why?
|
| Vimentin | 1 | 1999 | 66 | 0.010 |
Why?
|
| Osteoclasts | 1 | 1999 | 55 | 0.010 |
Why?
|
| Microscopy, Electron | 2 | 1992 | 396 | 0.010 |
Why?
|
| Mesoderm | 1 | 1999 | 113 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 1252 | 0.010 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1998 | 4 | 0.010 |
Why?
|
| Epithelium | 1 | 1999 | 362 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2000 | 437 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 2000 | 314 | 0.010 |
Why?
|
| Cattle | 2 | 1992 | 566 | 0.010 |
Why?
|
| Paternity | 1 | 1996 | 8 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1999 | 423 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2000 | 673 | 0.010 |
Why?
|
| Vaccination | 1 | 2002 | 952 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1997 | 293 | 0.010 |
Why?
|
| Peptide Chain Termination, Translational | 1 | 1975 | 3 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1982 | 834 | 0.010 |
Why?
|
| Rabbits | 1 | 1997 | 711 | 0.010 |
Why?
|
| Calcium | 1 | 1981 | 1098 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 1995 | 56 | 0.010 |
Why?
|
| Mitral Valve Prolapse | 1 | 1995 | 28 | 0.010 |
Why?
|
| Ventricular Dysfunction | 1 | 1995 | 25 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1995 | 80 | 0.010 |
Why?
|
| CHO Cells | 1 | 1995 | 157 | 0.010 |
Why?
|
| Systole | 1 | 1995 | 198 | 0.010 |
Why?
|
| Diastole | 1 | 1995 | 170 | 0.010 |
Why?
|
| Macrophages | 2 | 1975 | 618 | 0.010 |
Why?
|
| Cricetinae | 1 | 1995 | 414 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 1995 | 171 | 0.010 |
Why?
|
| Incidence | 1 | 2002 | 3144 | 0.010 |
Why?
|
| Genomic Imprinting | 1 | 1995 | 123 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1998 | 672 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1992 | 18 | 0.010 |
Why?
|
| Genomic Library | 1 | 1992 | 39 | 0.010 |
Why?
|
| Chromosomes, Fungal | 1 | 1992 | 49 | 0.010 |
Why?
|
| DNA Probes | 1 | 1992 | 124 | 0.010 |
Why?
|
| Indole Alkaloids | 1 | 1992 | 1 | 0.010 |
Why?
|
| Microvilli | 1 | 1992 | 72 | 0.010 |
Why?
|
| Surface Properties | 1 | 1992 | 83 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1992 | 93 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1995 | 1425 | 0.010 |
Why?
|
| Binding Sites | 1 | 1994 | 1297 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 75 | 0.010 |
Why?
|
| Gene Library | 1 | 1992 | 218 | 0.010 |
Why?
|
| Frontal Lobe | 1 | 1992 | 111 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 395 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 1992 | 115 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1992 | 214 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1992 | 303 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1990 | 106 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1990 | 117 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 1992 | 284 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1990 | 244 | 0.010 |
Why?
|
| Down-Regulation | 1 | 1992 | 701 | 0.010 |
Why?
|
| Egg White | 2 | 1975 | 10 | 0.000 |
Why?
|
| Ascitic Fluid | 2 | 1975 | 30 | 0.000 |
Why?
|
| Tissue Extracts | 1 | 1985 | 13 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1985 | 24 | 0.000 |
Why?
|
| Chickens | 2 | 1975 | 638 | 0.000 |
Why?
|
| Chromatography, Gel | 1 | 1985 | 97 | 0.000 |
Why?
|
| Synaptic Membranes | 1 | 1985 | 23 | 0.000 |
Why?
|
| Half-Life | 1 | 1985 | 157 | 0.000 |
Why?
|
| Zinc | 1 | 1985 | 128 | 0.000 |
Why?
|
| Ligation | 1 | 1983 | 135 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1992 | 5153 | 0.000 |
Why?
|
| Catheterization | 1 | 1983 | 236 | 0.000 |
Why?
|
| Pain Management | 1 | 1983 | 181 | 0.000 |
Why?
|
| Radiography | 1 | 1983 | 828 | 0.000 |
Why?
|
| Cholera Toxin | 1 | 1981 | 50 | 0.000 |
Why?
|
| Palliative Care | 1 | 1983 | 429 | 0.000 |
Why?
|
| Binding Sites, Antibody | 1 | 1975 | 98 | 0.000 |
Why?
|
| Antigens | 1 | 1975 | 158 | 0.000 |
Why?
|
| Immunologic Memory | 1 | 1975 | 185 | 0.000 |
Why?
|